Critical Alert Systems

nursecall.com

Critical Alert Systems develops easy to use, configurable, software-driven Nurse Call solutions for hospitals and healthcare organizations. Our goal is to enable patients to communicate their needs with their caregivers. We achieve this by providing highly reliable and context-rich messaging, rapidly delivering the patient request alerts and alarms to the right staff member no matter where they are within a facility. We are software at the core - focused entirely on optimizing clinical workflow, native integrations with communication devices & long term scalability.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

news image

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More

Medical

ANIXA BIOSCIENCES ANNOUNCES THE INITIATION OF ITS OVARIAN CANCER CAR-T PHASE 1 TRIAL AT MOFFITT CANCER CENTER

Anixa | March 31, 2022

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will ev...

Read More

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

news image

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

news image

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More
news image

Cell and Gene Therapy

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More
news image

Medical

ANIXA BIOSCIENCES ANNOUNCES THE INITIATION OF ITS OVARIAN CANCER CAR-T PHASE 1 TRIAL AT MOFFITT CANCER CENTER

Anixa | March 31, 2022

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will ev...

Read More
news image

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More
news image

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us